Metabolic maps showing the ratio of myo-inositol to N-acetylaspartate (mI/NAA) clearly depict small subcortical or juxtacortical lesions (circles) that appear inconspicuous at T1-weighted MRI (T1w)/fluid-attenuated inversion-recovery (FLAIR) imaging (indicated with arrows in three participants with multiple sclerosis). Image courtesy of Radiological Society of North America

Metabolic maps showing the ratio of myo-inositol to N-acetylaspartate (mI/NAA) clearly depict small subcortical or juxtacortical lesions (circles) that appear inconspicuous at T1-weighted MRI (T1w)/fluid-attenuated inversion-recovery (FLAIR) imaging (indicated with arrows in three participants with multiple sclerosis). Image courtesy of Radiological Society of North America


January 5, 2022 — A new neuroimaging technique can detect biochemical changes in the brains of people with multiple sclerosis (MS) early in the course of the disease, paving the way for faster treatment evaluation and other potential benefits, according to a study published in the journal Radiology.

MS is a disease of the central nervous system that can cause fatigue, pain and impaired coordination. It affects nearly 3 million people worldwide, and incidence is rising. There is no cure, but physical therapy and medications can slow its progression.

Lesions to the brain’s signal-carrying white matter are the most readily detectable manifestation of MS on MRI. The lesions, linked to the loss of the protective coating around white matter fibers called myelin, represent only macroscopic tissue damage. A means to find changes in the brain at an earlier microscopic or biochemical stage would be beneficial.

An advanced imaging technique known as proton MR spectroscopy is a promising tool in this effort. MR spectroscopy of the brain can detect several metabolites, or substances produced during metabolism, that have potential relevance for MS.

Researchers in Austria used the technique to compare biochemical changes in the brains of 65 people with MS with those of 20 healthy controls. They deployed an MRI scanner with a powerful 7-Tesla (T) magnet.

The results showed reduced levels of an amino acid derivative called N-acetylaspartate (NAA) in patients with MS. Lower levels of NAA have been linked to impaired integrity of neurons in the brain. People with MS also showed elevated levels of myo-inositol (MI), a compound involved in cell signaling. Higher levels are indicative of substantial inflammatory disease activity.

The metabolic alterations in normal-appearing white matter and cortical gray matter were associated with disability.

Researchers said the results show a potential role for 7T MR spectroscopic imaging in visualizing MS pathology beyond demyelinating lesions.

“MRI of neurochemicals enables the detection of changes in the brain of multiple sclerosis patients in regions that appear inconspicuous on conventional MRI,” said study senior author Wolfgang Bogner, Ph.D., from the High Field MR Centre at the Medical University of Vienna in Vienna, Austria. “The visualized changes in neurochemistry of normal-appearing brain tissue correlated with the patients’ disabilities.”

The changes detected by the new imaging technique have significant clinical applications, according to study lead author Eva Heckova, Ph.D., from the High Field MR Centre at the Medical University of Vienna.

“Some neurochemical changes, particularly those associated with neuroinflammation, occur early in the course of the disease and may not only be correlated with disability, but also be predictive of further progression such as the formation of multiple sclerosis lesions,” she said.

While more work is needed to confirm the results, the results support 7T MR spectroscopic imaging as a valuable new aid in the care of people with MS.

“If confirmed in longitudinal clinical studies, this new neuroimaging technique could become a standard imaging tool for initial diagnosis, for disease progression and therapy monitoring of multiple sclerosis patients and, in concert with established MRI, might contribute to neurologists’ treatment strategies,” Bogner said.

The researchers are working to further improve the image quality of the new technique and fully integrate it for use in routine clinical MRI scanners.

“In parallel, we will continue our ongoing longitudinal clinical study to validate its ability to detect clinically important pathologic changes in the brain of multiple sclerosis patients and to evaluate the efficacy of different treatment regimens earlier than other currently available clinical tools,”  Heckova said.

For more information: www.rsna.org

VIDEO: Large Radiology Study Reveals Spectrum of COVID-19 Brain Complications — Interview with Scott Faro, M.D.

Additional RSNA21 conference coverage can be found here.


Related Content

News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Orthopedic Imaging

Nov.10, 2025 — Medical imaging technology company Adaptix Ltd. has received 510(k) clearance from the U.S. Food and Drug ...

Time November 11, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Nov. 10, 2025 — There has been substantial progress in the past few years in the field of MRI in general and remote MR ...

Time November 11, 2025
arrow
News | RSNA 2025

Nov. 7, 2025 — Coreline Soft will introduce its chest AI platform AVIEW 2.0 at RSNA 2025 (Nov. 30 – Dec. 4, Chicago) ...

Time November 10, 2025
arrow
News | Contrast Media

Nov. 10, 2025 — Scientists at the University of Birmingham have developed a new class of MRI contrast agents – improving ...

Time November 10, 2025
arrow
News | Teleradiology

Nov. 4, 2025 — Virtual Radiologic (vRad) recently announced the successful commercialization of The vRad Platform — a ...

Time November 10, 2025
arrow
News | Lung Imaging

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...

Time November 07, 2025
arrow
Feature | Teleradiology | Kyle Hardner

Once viewed as a solution for after-hours coverage, teleradiology is rapidly expanding into a critical part of radiology ...

Time November 06, 2025
arrow
News | RSNA 2025

Nov. 4, 2025 — Altamont Software, a provider of enterprise medical connectivity solutions, has announced the ...

Time November 05, 2025
arrow
News | RSNA 2025

Oct. 31, 2025 — Echolight plans to demonstrate its bone density scanning technology at the Radiological Society of North ...

Time November 03, 2025
arrow
Subscribe Now